AhR ligand Aminoflavone inhibits alpha 6-integrin expression and breast cancer sphere-initiating capacity

作者：Brantley Eileen; Callero Mariana A; Berardi Damian E; Campbell Petreena; Rowland Leah; Zylstra Dain; Amis Louisa; Yee Michael; Simian Marina; Todaro Laura; Loaiza Perez Andrea I; Soto Ubaldo

来源：Cancer Letters, 2016, 376(1): 53-61.

DOI：10.1016/j.canlet.2016.03.025

• alpha 6-integrin
• Aminoflavone
• Aryl hydrocarbon receptor
• Mammospheres

Traditional chemotherapies debulk tumors but fail to produce long-term clinical remissions due to their inability to eradicate tumor-initiating cells (TICs). This necessitates therapy with activity against the TIC niche. Alpha6-integrin (alpha 6-integrin) promotes TIC growth. In contrast, aryl hydrocarbon receptor (AhR) signaling activation impedes the formation of mammospheres (clusters of cells enriched for TICs). We investigated the ability of AhR agonist Aminoflavone (AF) and AF pro-drug (AFP464) to disrupt mammospheres derived from breast cancer cells and a M05 mammary mouse model of breast cancer respectively. We further examined the capacity of AF and AFP464 to exhibit anticancer activity and modulate the expression of 'sternness' genes including alpha 6-integrin using immunofluorescence, flow cytometry and qRT-PCR analysis. AF disrupted mammospheres and prevented secondary mammosphere formation. In contrast, AF did not disrupt mammospheres derived from AhR ligand-unresponsive MCF-7 cells. AFP464 treatment suppressed M05 tumor growth and disrupted corresponding mammospheres. AF and AFP464 reduced the expression and percentage of cells that stained for 'sternness' markers including alpha 6-integrin in vitro and in vivo respectively. These data suggest AFP464 thwarts bulk breast tumor and TIC growth via AhR agonist-mediated alpha 6-integrin inhibition.

• 出版日期2016-6-28